A case of recurrent chronic eosinophilic pneumonia after switching from benralizumab to dupilumab
Open Access
- 3 January 2024
- journal article
- research article
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 47, 101968
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- How Can Dupilumab Cause Eosinophilic Pneumonia?Biomolecules, 2022
- Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE studyAllergology International, 2022
- Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical OutcomesJournal of Investigational Allergology and Clinical Immunology, 2022
- Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: IL-5-driven pathology?Allergology International, 2022
- Possible Mechanisms of Eosinophil Accumulation in Eosinophilic PneumoniaBiomolecules, 2020
- Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and managementAllergology International, 2019
- A case of chronic eosinophilic pneumonia in a patient treated with dupilumabTherapeutics and Clinical Risk Management, 2019
- Chronic eosinophilic pneumonia: clinical perspectivesTherapeutics and Clinical Risk Management, 2019
- Eosinophilic PneumoniasThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Eosinophilic Lung DiseasesClinics in Chest Medicine, 2016